XLONANIC
Market cap48mUSD
Dec 24, Last price
3.83GBP
1D
-2.31%
1Q
-25.49%
Jan 2017
-29.30%
IPO
-57.30%
Name
Agronomics Ltd
Chart & Performance
P/E
172.80
P/S
130.16
EPS
0.02
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-6.69%
Revenues
30m
+6,645.82%
Net income
22m
+275.22%
CFO
-24m
L-42.19%
Earnings
Dec 25, 2024
Profile
Agronomics Limited is a principal investment firm specializing in investments in funds, equity and equity related products. The firm invests in quoted and unquoted companies. It prefers to invest in the alternative proteins company with a focus on cellular agriculture, nascent industry of modern foods, biopharma sector and will establish a portfolio of investments in biotechnology and biopharmaceutical companies. The firm may also invest in shares of collective investment schemes with exposure to the biopharma sector and in long-term equity anticipation securities the underlying securities of which will be based on biopharma sector securities and/or indices relating to the biopharma Sector. It may invest in biopharma sector debt, where investments shall not exceed 15 per cent of the net asset value of the company. Agronomics Limited was founded on May 3, 2011 and is based in Ramsey, Isle of Man.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | |||||||||
Revenues | 29,703 6,645.82% | 440 69.29% | |||||||
Cost of revenue | 4,126 | 5,817 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 25,578 | (5,376) | |||||||
NOPBT Margin | 86.11% | ||||||||
Operating Taxes | 24,565 | 2,396 | |||||||
Tax Rate | 96.04% | ||||||||
NOPAT | 1,013 | (7,772) | |||||||
Net income | 22,374 275.22% | 5,963 -177.40% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 284 | 32,058 | |||||||
BB yield | -0.27% | -21.91% | |||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,946 | 149 | |||||||
Net debt | (169,867) | (146,296) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (24,402) | (42,208) | |||||||
CAPEX | |||||||||
Cash from investing activities | 10,024 | (20,024) | |||||||
Cash from financing activities | 1,014 | 31,254 | |||||||
FCF | 144,732 | (48,166) | |||||||
| Balance | |||||||||
Cash | 169,867 | 146,296 | |||||||
Long term investments | |||||||||
Excess cash | 168,382 | 146,274 | |||||||
Stockholders' equity | 33,776 | 14,057 | |||||||
Invested Capital | 134,481 | 129,856 | |||||||
ROIC | 0.77% | ||||||||
ROCE | 15.20% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 1,017,371 | 914,683 | |||||||
Price | 0.10 -35.00% | 0.16 -33.33% | |||||||
Market cap | 105,807 -27.70% | 146,349 -23.46% | |||||||
EV | (64,061) | 54 | |||||||
EBITDA | 25,578 | (5,376) | |||||||
EV/EBITDA | |||||||||
Interest | 344 | ||||||||
Interest/NOPBT | |||||||||